Anaptysbio (ANAB) Change in Accured Expenses (2016 - 2026)
Anaptysbio (ANAB) posted Change in Accured Expenses of -$17.8 million for Q1 2026, up 20.49% on a QoQ basis from -$22.4 million in Q4 2025, and up 25.86% year-over-year from -$14.2 million in Q1 2025.
Anaptysbio (ANAB) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Anaptysbio's Change in Accured Expenses history runs 11 years deep, the most recent figure standing at -$17.8 million for Q1 2026.
- Quarterly Change in Accured Expenses rose 25.86% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.1 million (down 53.92% YoY) and the FY2025 annual result came in at -$87.3 million, down 158.08% from the prior year.
- Change in Accured Expenses was -$17.8 million for Q1 2026 at Anaptysbio, up from -$22.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $8.5 million in Q1 2023 and bottomed at -$40.0 million in Q4 2024.
- A 5-year average of -$7.0 million and a median of -$1.5 million in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 8706.67% — and 2024, when it plunged 2573.36%.
- Anaptysbio's Change in Accured Expenses stood at $4.8 million in 2022, then plunged by 131.0% to -$1.5 million in 2023, then plunged by 2573.36% to -$40.0 million in 2024, then soared by 44.04% to -$22.4 million in 2025, then advanced by 20.49% to -$17.8 million in 2026.
- Business Quant data shows ANAB's Change in Accured Expenses at -$17.8 million in Q1 2026, -$22.4 million in Q4 2025, and -$18.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Anaptysbio | 1.57 Bn | 1.29 Bn | - | -17.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.82 Mn |
| Mar 31, 2026 | -17.82 Mn |
| Dec 31, 2025 | -22.41 Mn |
| Dec 31, 2025 | -22.41 Mn |
| Sep 30, 2025 | -18.56 Mn |
| Sep 30, 2025 | -18.56 Mn |
| Jun 30, 2025 | -22.32 Mn |
| Jun 30, 2025 | -22.32 Mn |
| Mar 31, 2025 | -24.03 Mn |
| Mar 31, 2025 | -24.03 Mn |
| Dec 31, 2024 | -40.05 Mn |
| Dec 31, 2024 | -40.05 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 8.02 Mn |
| Jun 30, 2024 | 8.02 Mn |
| Mar 31, 2024 | -5.17 Mn |
| Mar 31, 2024 | -5.17 Mn |
| Dec 31, 2023 | -1.50 Mn |
| Dec 31, 2023 | -1.50 Mn |